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CREB = cAMP responsive element binding; ECM = extracellular matrix; GABP = GA-binding protein; HLH = helix-loop-helix; ID4 = inhibitor of dif-
ferentiation 4; LOH = loss of heterozygosity.
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Introduction
The cloning of the BRCA1 gene, and later the BRCA2
gene, were major breakthroughs in our understanding of
breast cancer [1]. Both were isolated through traditional
positional cloning approaches [2,3] and are probably
responsible for the majority of familial breast cancer cases.
Our understanding of the multifunctional protein products
of the BRCA1 gene and why defects in the gene result in
breast and ovarian cancer is still in a state of flux. It
appears to be involved in multiple processes in the
nucleus, such as repair and recombination, as well as tran-
scriptional regulation (for review [4]). Recently, BRCA1
was reported to have the ability to bind directly to DNA,
particularly branched structures [5], and regulates the key
G2/M checkpoint protein Chk1 [6]. BRCA1 has also been
shown to induce large-scale chromatin unfolding [7],
which may play a role in both transcription and repair.
While the specific roles of BRCA1 continue to be clari-
fied, it is clear that functional BRCA1 protein is required to
prevent breast transformation. Selective inactivation of
BRCA1 in the breast results in blunted ductal develop-
ment, breast hyperplasia and tumour formation [8].
Soon after its isolation, it became apparent that somatic
mutations in the BRCA1 gene do not play a major role in
sporadic breast tumour development. Specifically, no
coding region mutations have been found [9] and noncod-
ing regulatory region mutations are extremely rare [10,11].
Because sporadic tumours account for more than 90% of
the total breast cancer burden, these findings were initially a
major disappointment. However, a key study suggested that
BRCA1 expression levels are reduced in sporadic tumours
[12]. RNase A protection assays were used to examine
mRNA levels in 19 sporadic tumour samples, and a consis-
tent decrease in BRCA1 mRNA levels was observed in
invasive tumours as compared with either paired normal
tissue or ductal carcinoma in situ. The significance of this
finding was enhanced when it was shown that decreasing
BRCA1 levels increased the growth of tumour cells and that
expression of BRCA1 led to growth arrest and apoptosis.
Since then a number of other studies have confirmed this
correlation and extended the observation.
One of the largest studies used 142 sporadic tumour
samples and found a general correlation between grade
Germ-line mutations in the BRCA1 tumour suppressor gene contribute to familial breast tumour
formation, but there is no evidence for direct mutation of the BRCA1 gene in the sporadic form of the
disease. In contrast, decreased expression of the BRCA1 gene has been shown to be common in
sporadic tumours, and the magnitude of the decrease correlates with disease progression. BRCA1
expression is also tightly regulated during normal breast development. Determining how these
developmental regulators of BRCA1 expression are co-opted during breast tumourigenesis could lead
to a better understanding of sporadic breast cancer aetiology and the generation of novel therapeutic
strategies aimed at preventing sporadic breast tumour progression.
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and decreased BRCA1 expression, with 20% of tumours
showing complete loss of BRCA1 protein [13]. High-
grade tumours generally have the lowest levels of BRCA1
[14] and exhibit higher proliferation rates [15]. Correla-
tions between low BRCA1 levels, tumour grade, metasta-
sis and prognostic markers such as oestrogen receptor
status have also been made [16,17]. An inverse associa-
tion with elevated c-erbB-2 levels has also been reported
[18]. A recent study of 175 patients indicated an adverse
effect on disease-free survival of low levels of BRCA1
[19]. Similar studies have correlated decreased BRCA1
levels with development of sporadic ovarian cancer [20].
This would be in accordance with the common function of
BRCA1 as a tumour suppressor in both of these tissues.
Overall, these findings suggest a model in which loss of
BRCA1 activity, either by germ-line mutations or by down-
regulation of gene expression, leads to tumour formation in
appropriate target tissues.
The data generated from the clinical studies cited above
strongly suggest that decreased BRCA1 expression con-
tributes to sporadic breast tumour progression. The func-
tional importance of such a decrease has been confirmed
by experimental manipulations of BRCA1 expression in
cultured cells [12]. Regulation of protein stability may
affect BRCA1 levels in certain circumstances [21], but
this aspect of BRCA1 regulation is outside the scope of
the present review. Therefore, here we address the most
likely mechanisms for permanent decrease in BRCA1
expression in sporadic breast tumours. We then review
the factors and signalling pathways that may be responsi-
ble for the modulation of BRCA1 expression in various
developmental contexts. Finally, we discuss how disrup-
tion of these pathways could contribute to development of
sporadic breast cancer, and whether transcription factors
that regulate BRCA1 are candidate sporadic breast
cancer genes.
Loss of heterozygosity and methylation of the
BRCA1 promoter
There are several potential mechanisms that could lead to
a permanent decrease in BRCA1 levels in sporadic breast
tumours. One such mechanism is allelic loss of heterozy-
gosity (LOH), in the absence of mutations (Fig. 1a), which
has been observed at the BRCA1 locus in conjunction
with a decrease in the steady-state levels of BRCA1
protein [22,23]. Normally, LOH alone would not contribute
to a decrease in gene expression because the net result is
two identical but genetically normal alleles. If one allele
was subject to inactivation by methylation (see below),
then LOH would lead to the presence of two methylated
alleles and loss of expression. The observation of allele-
specific expression of BRCA1 (Fig. 1b), in which examina-
tion of BRCA1 mRNA indicated that only one of the two
genes was being expressed [24], could represent prelimi-
nary methylation of one allele. Currently, however, no
studies have clearly demonstrated a functional link
between LOH and promoter methylation.
Methylation, which can be permanent and heritable, is
associated with decreased tumour suppressor gene
expression in a number of disease contexts [25]. Examina-
tion of methylation patterns in the BRCA1 promoter region
indicated that preferential methylation of some sites
occurs (Fig. 1c), apparently only in tumours [26–30].
Moreover, promoter methylation may result in very low
levels of BRCA1 [31]. Methylation is associated with
greater chromatin compaction and lack of accessibility
[32]. As with other systems, there is a question of whether
methylation itself causes the initial decrease in BRCA1
expression or whether an initial transient decrease in tran-
scriptional activity could have been the impetus for estab-
lishment of permanent methylation. Methylation appears to
be a significant factor in BRCA1 regulation only in a small
proportion of sporadic breast tumours [33]. Therefore, it is
necessary to postulate that promoter silencing occurs by
some other means in the majority of cases.
The BRCA1 promoter
The structure of the human BRCA1 locus is complicated
(Fig. 2) in that it includes a partial duplication that results
in a pseudo-BRCA1 gene and two distinct genes (i.e.
NBR1 and  NBR2) [34,35] which are divergently tran-
scribed from both the pseudo-gene and BRCA1. This
structure is not found in the mouse [36], which may be
partly responsible for the differences between human and
mouse breast cancer models (i.e. heterozygous brca1
knockout mice do not develop breast cancer, whereas
human carriers do). The BRCA1 and  NBR2 genes are
separated by little more than 200 base pairs, and their
transcription is divergent (Fig. 3). This region serves as the
primary proximal promoter for the major breast-specific
transcription start site located in exon 1a of BRCA1 [37].
Several initial studies of the BRCA1 promoter have been
reported that have identified a possible upstream repres-
sor element [38] and a positive element that is located
some 200 base pairs upstream of this start site [39]. This
region was able to direct expression in either the BRCA1
or NBR2 direction, suggesting that it functions as a bidi-
rectional transcriptional element [40]. There is some evi-
dence to suggest that the NBR2 and BRCA1 genes may
actually be reciprocally regulated. In a number of cell lines,
higher levels of NBR2 expression are correlated with low
BRCA1 levels [41]. This may reflect competition between
the promoters for RNA polymerase II; it also suggests that
activation of the NBR2 promoter could lead to decreased
BRCA1 expression (Fig. 1d).
In culture BRCA1 expression increases in replicating cells
[42], and stimulation of BRCA1 expression by oestrogen
[43,44] appears to result from the effect of this hormone
on breast cell growth [45]. This proliferation-mediated47
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Figure 1
Potential mechanisms for the reducing BRCA1 expression. Schematics of the two BRCA1 alleles are shown. (a) Endo-reduplication of a
methylated allele would lead to complete loss of expression. (b) Expression from only one allele could be indicative of methylation of one of the
promoters. (c) Methylation of both promoters through an unidentified mechanism would lead to a dramatic decrease in expression. (d) Increased
NBR2 expression could lead to decreased BRCA1 expression. (e) p53 could inhibit factors such as E2F. (f) Loss of DNA binding by the
GABP-α/β complex leads to decreased expression. (g) ID4 expression leads to the down regulation of the BRCA1 promoter, presumably through
interaction with a transcription factor that normally regulates the promoter. (h) BRCA1 and ID4 levels appear to be coregulated.
Figure 2
The structure of the human and mouse BRCA1 loci are shown. Transcription initiation sites are indicated by arrows. The general exon structure is
indicated by the variously shaded boxes. The patterned box indicates the location of an acidic ribosomal phosphoprotein P1 pseudocopy [34],
which appears to have been inserted into the region between NBR1 and the BRCA1 pseudo-gene. The BRCA1 gene appears to have two
alternative first exons, although the 1A exon appears to be used much more frequently.48
increase may act through an E2F site that has been char-
acterized in the proximal promoter (Fig. 3) [46]. Con-
versely, p53 may inhibit BRCA1 expression by preventing
E2F binding to this site (Fig. 1e) [47]. A negative regula-
tory site within the first intron has also been characterized,
but the associated proteins have not been identified [48].
Studies of the methylation pattern of the promoter sug-
gested that a potential cAMP-responsive element binding
(CREB) protein site might be important for promoter func-
tion (Fig. 3) [26]. It was subsequently shown that this
CREB site is a strong positive transcriptional element
[49], although the site does not confer cAMP responsive-
ness on the promoter, as might be expected [50].
One transcription factor binding site has been identified
that is critical for BRCA1 expression, but in a cell-line-spe-
cific manner. This RIBS element (Fig. 3) has been shown
to bind the multisubunit ets protein GA-binding protein
(GABP)-α/β and acts as an activator in MCF-7 cells but
not in T47-D cells [51]. This site is within the positive
element previously described [39] and is included within
the minimal bidirectional promoter element (Fig. 3) [40].
GABP-α and GABP-β subunits have been shown to be
present in both cell lines, but its DNA-binding activity was
reduced in T47-D cells [51]. It is possible that mutation in
one of the GABP subunits itself, or disruption of an
upstream regulator, is responsible for loss of GABP-
dependent positive transcriptional activity in these cells
(Fig. 1f). An elegant selection screening system using a
library of riboyzmes was also able to identify a potential
regulator of BRCA1 expression [52]. Inactivation of the
helix-loop-helix (HLH) protein inhibitor of differentiation 4
(ID4) was able to increase expression of BRCA1 in MCF-
7 cells (Fig. 1g). There appears to be a reciprocal relation-
ship between the levels of ID4 and BRCA1, and ID4
expression may be regulated by oestrogen or by oestro-
gen’s ability to induce growth. An interesting correlation
between ID4 and BRCA1 expression has also come from
efforts to identify transcriptionally regulated targets of
BRCA1. Microarray analysis revealed that ID4 mRNA
levels were increased upon BRCA1 induction [53]. Fur-
thermore, there was a general positive correlation
between BRCA1 and ID4 levels in a variety of breast and
ovarian tumours [53]. This is in contrast to the inverse rela-
tionship found by artificial manipulation of ID4 levels [51].
This suggests that ID4 may be involved in a developmental
regulatory loop that is disrupted during sporadic tumouri-
genesis (Fig. 1h).
Developmental regulation of BRCA1
expression in mammary gland
The developmental regulation of BRCA1 expression has
been most extensively studied in the mouse [54–58].
During early embryogenesis BRCA1 (denoted brca1 in
the mouse) is expressed diffusely in all three germ layers.
Later, during foetal development, brca1 expression is
highest in condensed tissues undergoing considerable
proliferative, differentiative and morphogenic changes.
These include the following: spinal ganglia and the neuro-
epithelium of the eye (neuroectoderm derived); somites
and cartilage (mesoderm derived); liver and lung (endo-
derm derived); lense of the eye; and basal proliferative
layers of the epidermis (ectodermally derived). Although
expression of brca1 in the embryonic mammary gland has
not been described, it is reasonable to suggest that its
expression might parallel that seen in the epidermis
because the glandular rudiment first forms as an invagina-
tion of this tissue.
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Figure 3
The sequence of the promoter region between the NBR2 and the BRCA1 genes is indicated. The transcriptional start sites are indicated by the left
and right pointing arrows for the respective genes. Binding sites for transcription factors identified as being important for promoter activity are
boxed. The minimal bidirectional promoter [40] is indicated by the dashed line. The first exon of the BRCA1 gene is indicated by the shaded box.
CpG dinucleotides that are potentially methylated are shown in red. The location of an EcoRI and Sac I are indicated by thick lines.49
At birth the mouse mammary gland consists of a small
number of epithelial ducts that radiate from the nipple a
short distance into the underlying stromal fat pad. Before
puberty the mammary ducts elongate into the fat pad at a
rate that is similar to the overall growth of the animal.
Further development of the gland takes place at puberty
and during adult cycles of pregnancy, lactation and involu-
tion [59]. At puberty the ends of the ducts swell to form
the proliferative terminal end-buds, which strongly express
brca1 and initiate rapid ductal branching and elongation to
the margins of the fat pad. After puberty, brca1 levels fall
in the quiescent adult virgin gland. With the onset of preg-
nancy the terminal end-buds proliferate, branch and
expand to form epithelial alveolar sacs. Throughout preg-
nancy brca1 is expressed at high levels in these develop-
ing alveoli. Later, during lactation, brca1 levels fall
gradually as alveolar cells cease proliferating, terminally
differentiate and produce milk. After weaning, milk produc-
tion ceases, brca1 levels rise, and within a few days a
massive apoptotic event is triggered. This drives involution
and returns the gland to its quiescent state, whereupon
brca1 levels once again fall. Therefore, in the postnatal
mammary gland epithelial brca1 expression is induced in
periodic waves that correspond to defined developmental
periods in which intense proliferation, morphogenesis
and/or apoptosis take place (Fig. 4). Given these observa-
tions, it is not unreasonable to expect that the molecular
regulators of these developmental changes might also
regulate brca1 expression.
Molecular regulators of mammary
development
Mammary development is directed by at least three
classes of molecular regulators. The first class consists of
the systemic hormones, which are produced at distant
sites but act within the mammary gland to initiate develop-
mental change. Three such hormones, namely oestrogen
[43,44], progesterone [60] and prolactin [61], have all
been shown to upregulate BRCA1 expression. In culture,
this upregulation is manifested under conditions that are
conducive to nondifferentiative cellular proliferation [45].
In vivo, this would occur during pregnancy, when all three
hormones contribute to the massive proliferative burst
before alveolar morphogenesis and differentiation [62].
Interestingly, when prolactin later acts as a lactogenic, dif-
ferentiative agent, it no longer upregulates BRCA1 expres-
sion [56].
The second class of regulators consists of soluble
microenvironmental factors. These molecules are pro-
duced within the mammary tissues proper and they act
over very short distances, often in a paracrine manner, to
mediate functional interactions between the stromal and
epithelial compartments of the gland [63]. Two such
factors are hepatocyte growth factor and neuregulin,
which mediate ductal branching and alveolar morphogen-
esis, respectively [64]. The ability of these agents to regu-
late BRCA1 expression in an appropriate developmental
context in culture has not yet been determined. However,
neuregulin, which signals through the erbB tyrosine kinase
receptors, is active in vivo at the transition to nonprolifera-
tive, terminal differentiation when BRCA1 levels fall dra-
matically. Interestingly, one of the known regulators of the
BRCA1 promoter, namely GABP-α/β [51], is a down-
stream mediator of neuregulin signalling in nerve cells [65].
The third class of mammary-specific regulators are extra-
cellular matrix (ECM) proteins. For example, laminin, a
glycoprotein that is located in the specialized basement
membrane ECM, binds to cell surface integrin receptors
and generates signals within the mammary epithelium that
are required for lactational differentiation [66,67]. Further-
more, a metalloproteinase-mediated destruction of laminin
triggers alveolar cell apoptosis during involution [68,69].
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Figure 4
Brca1 expression in the mouse mammary gland. The line represents relative brca1 expression levels and is regulated in periodic waves during
mammary gland development. Levels are low in the quiescent periods before puberty, in the virgin adult gland and in the resting gland. Levels are
also low during lactational terminal differentiation. Levels are high during the proliferative periods at puberty and during pregnancy. Levels are also
high during the apoptotic period of involution after weaning.50
Therefore, an intact laminin-containing basement mem-
brane may be a negative regulator of BRCA1 expression in
differentiated mammary epithelial cells, and that this nega-
tive regulation could be released during involution [70].
Conclusion
BRCA1 expression is clearly modulated by developmental
regulators in the normal mammary gland. At the same time,
decreased BRCA1 expression is an early event in the
process of breast transformation, and progresses with the
degree of malignancy. Given the known molecular func-
tions of BRCA1, it is reasonable to assume that such
decreases lead to a relaxation in genome surveillance. This
relaxation would not be deleterious during normal develop-
ment because BRCA1 levels are lowest when mammary
epithelial cells are either quiescent or terminally differenti-
ated. However, changes in BRCA1 levels may also play an
active role in regulating developmental processes, such as
inducing postlactational regression. A number of transcrip-
tion factors have been identified that regulate BRCA1
expression. Positive regulators such as E2F and GABP-
α/β, as well as repressors such as ID4, combine to
produce the varied developmental expression that is
observed in vivo. These factors presumably lie at the end
of a variety of signalling pathways that are initiated by mol-
ecular regulators of developmental change in the
mammary gland. Importantly, many of the signals initiated
by these regulators have themselves been implicated in
mammary oncogenesis. Thus, we propose that mutations
in the transcription factors themselves or alterations to the
developmentally regulated signalling pathways that modu-
late their activity contribute to the inappropriate repression
of BRCA1 expression. Obviously, these two possibilities
are not mutually exclusive and could be overlapping.
One key regulator of terminal differentiation and BRCA1
repression is the basement membrane ECM. Cross-talk
occurs between basement membrane-mediated signalling,
prolactin signalling and morphogenic erbB receptor sig-
nalling during development [67,66,71,72]. This would
ensure that in quiescent cells the ECM signal prevents
BRCA1 induction, but during growth this blockade is
lifted, and prolactin and erbB signals, which are prolifera-
tive outside the context of morphogenesis and lactational
differentiation, result in BRCA1 induction. Tumour cell sur-
vival presumably requires abrogation of this BRCA1
induction. There are observational and experimental data
that indirectly support this tentative hypothesis. First, in
sporadic tumours BRCA1 levels are most affected after
progression from ductal carcinoma in situ [12], a time
when the basement membrane is undergoing chronic
remodelling. Second, mammary-specific expression of an
activated metalloprotease that remodels the basement
membrane [73,74] causes a morphogenic and stochastic
tumour formation in transgenic mice that is reminiscent of
the phenotype observed in the targeted BRCA1 knockout
[8]. Third, a developmentally inappropriate integrin signal
switching that contributes to breast tumour progression
causes erbB signalling to become oncogenic [75,76].
Fourth, oncogenic erbB signalling and BRCA1 expression
are inversely correlated in tumour cells [18]. Finally, forced
expression of ID1, which is closely related to the BRCA1
repressor ID4, causes mammary epithelial cells to prolifer-
ate rather than differentiate when they are exposed to a
basement membrane ECM [77,78].
Transcription factors that regulate the BRCA1 promoter
directly modulate the production of this tumour suppres-
sor, and thus their loss or gain of function will have the
same functional consequences as inactivation of BRCA1
itself. This raises the question of whether these factors act
as sporadic breast cancer genes. Optimal BRCA1 expres-
sion requires the concerted action of a number of tran-
scription factors, so that inactivation of any one protein will
affect BRCA1 levels. Given a random distribution of spo-
radic mutations in the genome, it may be more likely that
one of a number of different transcription factor genes
would be a target, rather than the BRCA1 gene itself. In
addition, loss of activity from a single allele of a transcrip-
tion factor gene may be sufficient to decrease BRCA1
expression significantly, with functional consequences.
This may explain why sporadic mutations in BRCA1 have
not been observed, because these may be rarer events
than transcription factor gene mutations. Furthermore, as
discussed above, loss of transcriptional regulators of
BRCA1 may not require actual mutational events. Disrup-
tion of the signalling pathways that regulate BRCA1
expression could have long-term consequences for the
associated transcriptional regulators, which persist
through subsequent progression events. In some cases,
BRCA1 transcription is reduced sufficiently for methyla-
tion of the promoter to occur, creating a self-sustaining
repressed state. It may be possible to restore BRCA1
expression in tumours. This could be achieved by the use
of demethylating agents such as deazacytadine, inducing
alternative pathways where mutations have blocked other
factors, or restoring developmental signals that have been
co-opted. Induction of BRCA1 expression has been
shown to induce apoptosis or reduce growth in tumour
cells [12], and offers an alternative therapeutic approach
that may be tumour specific.
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